- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.02. | Pila Pharma AB: Pila Pharma today publishes the Company's year-end report for the period January - December 2025. | 175 | GlobeNewswire (Europe) | The report can be found on the Company's website:
https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT
SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025)
Operating income amounted to... ► Artikel lesen | |
| 26.01. | Pila Pharma AB: Pila Pharma Signs With New Clinical Cro To Prepare For Clinical Phase In Obesity After Preclinical Obesity Studies | 190 | GlobeNewswire (Europe) | Malmö, 26 January 2026
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that... ► Artikel lesen | |
| 03.11.25 | Pila Pharma share issue for obesity drug research is massively oversubscribed | 3 | The Armchair Trader | ||
| 30.09.25 | Pila Pharma AB: Pila Pharma Enters Into Agreement With The Danish preclinical Contract Research Organisation Gubra On Preclinical Trials Of Xen-d0501 In Obesity | 538 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest... ► Artikel lesen | |
| 27.08.25 | Pila Pharma AB: Pila Pharma Publishes Interim Report (1 January - 30 June 2025) | 534 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today publishes the Company's interim... ► Artikel lesen | |
| 31.07.25 | Pila Pharma AB: PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares | 1.153 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announces that the last day of trading in paid subscribed units (Sw. BTU) in connection with the Company's rights issue of units which the Board... ► Artikel lesen | |
| 26.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.06.2025 | 1.026 | Xetra Newsboard | Das Instrument 4LG CH0371153492 LANDIS+GYR GROUP AG SF 10 EQUITY wird cum Kapitalmassnahme gehandelt am 26.06.2025 und ex Kapitalmassnahme am 27.06.2025 The instrument 4LG CH0371153492 LANDIS+GYR GROUP... ► Artikel lesen | |
| PILA PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.06.25 | Pila Pharma AB: Pila Pharma Publishes Prospectus In Connection With The Announced Rights Issue Of Units | 274 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 14,600 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | 0,00 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | 0,00 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,000 | +1,13 % | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | 0,00 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| LENZ THERAPEUTICS | 10,480 | -8,79 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 7,940 | 0,00 % | Kyverna Therapeutics: Ein kommender Biotech-Star? | Die Aktie von Kyverna Therapeutics rückt zunehmend in den Blick von Investoren, die auf bahnbrechende CAR-T-Therapien im Autoimmunbereich setzen. Mit vielversprechenden Studiendaten und einer bevorstehenden... ► Artikel lesen | |
| NUVALENT | 94,82 | 0,00 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,325 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan |
PILA PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,67 % bei einem Aktienkurs von 0,098 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.